Evaluation of efficacy and safety of apatinib for patients with recurrent epithelial ovari-an cancer
10.3969/j.issn.1000-8179.2019.12.159
- VernacularTitle:甲磺酸阿帕替尼治疗二线化疗失败上皮性卵巢癌的疗效分析
- Author:
Lu SUN
1
;
Xiangyu LIU
;
Hu YU
;
Ke WANG
;
Wenxin LIU
Author Information
1. 天津医科大学肿瘤医院妇科肿瘤科
- Keywords:
apatinib;
epithelial ovarian cancer (EOC);
angiogenesis inhibitor;
recurrence
- From:
Chinese Journal of Clinical Oncology
2019;46(12):627-630
- CountryChina
- Language:Chinese
-
Abstract:
To assess the efficacy and safety of apatinib for patients with epithelial ovarian cancer (EOC) who had failed in second-line chemotherapy. Methods: The clinical data of 46 patients with recurrent EOC who had failed in second-line chemotherapy and were admitted to the Cancer Hospital of Tianjin Medical University from September 2017 to November 2018 were collected. The treatment efficacy of apatinib was evaluated, and treatment-related adverse events (AEs) were recorded to evaluate its safety. Results:A total of 46 eligible patients were enrolled. The median follow-up time was 12 months. The median overall survival (OS) was 6 months (range 2-15 months). The objective response rate (ORR) was 26.1% (12/46 patients), and the disease control rate (DCR) was 86.9% (40/46 patients). AEs occurred in 30 patients (65.2%), and were mainly of grade 1-2. The most common treatment-related AEs were hypertension (39.1%) and hand-foot-skin syndrome (30.4%); only one patient experienced grade 3 treatment-related hyperten-sion. All grade 1-2 AEs could be recovered rapidly and well-tolerated after treatment with medication. Conclusions: Apatinib may be a safe and effective option for patients with advanced EOC who had failed in second-line chemotherapy. Further Studies are warranted in large-scale clinical trials.
